vs

Side-by-side financial comparison of Iveda Solutions, Inc. (IVDA) and TherapeuticsMD, Inc. (TXMD). Click either name above to swap in a different company.

TherapeuticsMD, Inc. is the larger business by last-quarter revenue ($893.0K vs $626.0K, roughly 1.4× Iveda Solutions, Inc.). On growth, TherapeuticsMD, Inc. posted the faster year-over-year revenue change (33.9% vs -64.1%). Over the past eight quarters, TherapeuticsMD, Inc.'s revenue compounded faster (68.9% CAGR vs 34.4%).

Iveda Solutions, Inc. is a technology provider specializing in cloud-based AI video surveillance, IoT-enabled smart sensing, and integrated smart city solutions. It serves public sector, enterprise, and education clients across North America and Asia, with core offerings covering remote security monitoring, smart facility management, and real-time data analysis tools for public safety use cases.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

IVDA vs TXMD — Head-to-Head

Bigger by revenue
TXMD
TXMD
1.4× larger
TXMD
$893.0K
$626.0K
IVDA
Growing faster (revenue YoY)
TXMD
TXMD
+97.9% gap
TXMD
33.9%
-64.1%
IVDA
Faster 2-yr revenue CAGR
TXMD
TXMD
Annualised
TXMD
68.9%
34.4%
IVDA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IVDA
IVDA
TXMD
TXMD
Revenue
$626.0K
$893.0K
Net Profit
$-1.6M
Gross Margin
3.6%
Operating Margin
-262.7%
Net Margin
-258.6%
Revenue YoY
-64.1%
33.9%
Net Profit YoY
-7.1%
-345.6%
EPS (diluted)
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVDA
IVDA
TXMD
TXMD
Q4 25
$626.0K
$893.0K
Q3 25
$1.7M
$784.0K
Q2 25
$1.5M
$952.0K
Q1 25
$1.5M
$393.0K
Q4 24
$1.7M
$667.0K
Q3 24
$2.4M
$547.0K
Q2 24
$1.5M
$234.0K
Q1 24
$346.8K
$313.0K
Net Profit
IVDA
IVDA
TXMD
TXMD
Q4 25
$-1.6M
Q3 25
$-221.3K
$152.0K
Q2 25
$-564.2K
$551.0K
Q1 25
$-793.7K
$-653.0K
Q4 24
$-1.5M
Q3 24
$-581.4K
$-609.0K
Q2 24
$-599.0K
$-1.1M
Q1 24
$-1.3M
$-734.0K
Gross Margin
IVDA
IVDA
TXMD
TXMD
Q4 25
3.6%
Q3 25
31.3%
Q2 25
29.1%
Q1 25
19.5%
Q4 24
11.9%
Q3 24
17.1%
Q2 24
32.7%
Q1 24
52.5%
Operating Margin
IVDA
IVDA
TXMD
TXMD
Q4 25
-262.7%
Q3 25
-13.0%
-109.9%
Q2 25
-34.8%
-73.0%
Q1 25
-56.7%
-221.6%
Q4 24
-87.3%
Q3 24
-25.4%
-207.3%
Q2 24
-39.7%
-1191.9%
Q1 24
-384.1%
-364.9%
Net Margin
IVDA
IVDA
TXMD
TXMD
Q4 25
-258.6%
Q3 25
-13.4%
19.4%
Q2 25
-36.9%
57.9%
Q1 25
-53.8%
-166.2%
Q4 24
-86.7%
Q3 24
-24.2%
-111.3%
Q2 24
-39.0%
-465.8%
Q1 24
-371.9%
-234.5%
EPS (diluted)
IVDA
IVDA
TXMD
TXMD
Q4 25
$-0.33
Q3 25
$-0.07
$0.01
Q2 25
$-0.20
$0.05
Q1 25
$-0.28
$-0.06
Q4 24
$-0.60
Q3 24
$-0.27
$-0.05
Q2 24
$-0.30
$-0.09
Q1 24
$-0.64
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVDA
IVDA
TXMD
TXMD
Cash + ST InvestmentsLiquidity on hand
$5.2M
Total DebtLower is stronger
$393.4K
Stockholders' EquityBook value
$4.8M
$26.9M
Total Assets
$6.4M
$37.7M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVDA
IVDA
TXMD
TXMD
Q4 25
$5.2M
Q3 25
$3.3M
Q2 25
$1.6M
Q1 25
$2.5M
$5.7M
Q4 24
$2.6M
$5.1M
Q3 24
$3.6M
Q2 24
$2.9M
Q1 24
$3.9M
Total Debt
IVDA
IVDA
TXMD
TXMD
Q4 25
$393.4K
Q3 25
$306.4K
Q2 25
$365.3K
Q1 25
$340.8K
Q4 24
$376.2K
Q3 24
$545.9K
Q2 24
$564.0K
Q1 24
$480.0K
Stockholders' Equity
IVDA
IVDA
TXMD
TXMD
Q4 25
$4.8M
$26.9M
Q3 25
$3.8M
$27.4M
Q2 25
$1.5M
$27.3M
Q1 25
$1.7M
$26.7M
Q4 24
$2.5M
$27.4M
Q3 24
$4.1M
$27.1M
Q2 24
$2.8M
$27.7M
Q1 24
$3.3M
$28.7M
Total Assets
IVDA
IVDA
TXMD
TXMD
Q4 25
$6.4M
$37.7M
Q3 25
$5.8M
$38.7M
Q2 25
$4.4M
$38.5M
Q1 25
$4.5M
$38.2M
Q4 24
$5.2M
$38.8M
Q3 24
$9.1M
Q2 24
$6.8M
$40.1M
Q1 24
$6.6M
Debt / Equity
IVDA
IVDA
TXMD
TXMD
Q4 25
0.08×
Q3 25
0.08×
Q2 25
0.25×
Q1 25
0.20×
Q4 24
0.15×
Q3 24
0.13×
Q2 24
0.20×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVDA
IVDA
TXMD
TXMD
Operating Cash FlowLast quarter
$-252.4K
$2.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVDA
IVDA
TXMD
TXMD
Q4 25
$-252.4K
$2.5M
Q3 25
$-317.0K
$999.0K
Q2 25
$-1.3M
$381.0K
Q1 25
$-126.0K
$699.0K
Q4 24
$-889.8K
$1.2M
Q3 24
$-1.2M
$-71.0K
Q2 24
$-999.7K
$1.5M
Q1 24
$-1.3M
$-229.0K
Free Cash Flow
IVDA
IVDA
TXMD
TXMD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-889.8K
Q3 24
$-1.5M
Q2 24
$-1.1M
Q1 24
$-1.5M
FCF Margin
IVDA
IVDA
TXMD
TXMD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-51.1%
Q3 24
-64.1%
Q2 24
-72.6%
Q1 24
-427.3%
Capex Intensity
IVDA
IVDA
TXMD
TXMD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.0%
Q3 24
12.5%
Q2 24
7.5%
Q1 24
54.3%
Cash Conversion
IVDA
IVDA
TXMD
TXMD
Q4 25
Q3 25
6.57×
Q2 25
0.69×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons